The ALG11 antibody is a research tool designed to target the ALG11 protein, a key enzyme in the N-linked glycosylation pathway. ALG11. encoded by the *ALG11* gene in humans, is an α-1.2-mannosyltransferase localized to the endoplasmic reticulum (ER). It catalyzes the addition of the fifth and sixth mannose residues to the lipid-linked oligosaccharide (LLO) precursor (Man₅GlcNAc₂-PP-Dol), forming Man₆GlcNAc₂-PP-Dol, a critical step in synthesizing the glycan core required for proper protein folding and secretion. Mutations in *ALG11* are linked to congenital disorders of glycosylation (CDG), specifically ALG11-CDG (CDG-Ip), a severe multisystem disease characterized by developmental delays, seizures, and impaired neurological function. The ALG11 antibody enables researchers to study the expression, localization, and functional role of ALG11 in glycosylation, cellular homeostasis, and disease mechanisms. It is widely used in Western blotting, immunofluorescence, and immunohistochemistry to investigate ER-associated processes, glycosylation defects, and potential therapeutic strategies for CDG. By detecting ALG11. this antibody contributes to understanding the molecular basis of glycosylation disorders and their broader implications in cellular biology and human health.